Amarin Sues FDA Over Vascepa Market Exclusivity Denial
Amarin Corp. PLC sued the U.S. Food and Drug Administration in Washington, D.C., federal court Thursday, alleging the regulator wrongly denied its bid for a market exclusivity period for high blood...To view the full article, register now.
Already a subscriber? Click here to view full article